FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 325:81-86 July 11, 1991 Number 2 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. A recent randomized controlled trial of intravenous immune globulin in patients with chronic lymphocytic leukemia and hypogammaglobulinemia demonstrated a statistically significant reduction in the rate of bacterial infections among patients who received intravenous immune globulin. We used decision-analysis techniques to determine whether prophylactic intravenous immune globulin is likely to result in an overall clinical benefit to patients who receive this treatment and to examine its cost effectiveness. METHODS. We constructed a model to compare two strategies: treatment with intravenous immune globulin at a dose of 400 mg per kilogram of body weight every three weeks and no immune globulin therapy. Baseline estimates of the efficacy of intravenous immune globulin were derived from the published results of the randomized trial. The costs of treatment, complications, and infections were estimated on the basis of component costs. Health outcomes were measured in terms of gains in quality-adjusted life expectancy. RESULTS. Intravenous immune globulin therapy can result in a loss of quality-adjusted life expectancy when the inconvenience of treatment is taken into account. If the inconvenience of treatment is not considered, therapy results in a gain of 0.8 quality-adjusted days per patient per year of therapy at a cost of $6 million per quality-adjusted life-year gained. CONCLUSIONS. Decision-analysis modeling may be applied to the results of randomized controlled trials to assess the potential clinical and financial effects of adopting the intervention in medical practice. In the case of intravenous immune globulin therapy in patients with chronic lymphocytic leukemia and hypogammaglobulinemia, this type of analysis suggests that treatment might not result in improved quality or length of life and that it is extraordinarily expensive in comparison with other treatments generally accepted as cost effective.

Source Information

Division of Clinical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.

This article has been cited by other articles:

• Hamblin, A. D., Hamblin, T. J. (2008). The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 87: 49-62 [Abstract] [Full Text]  
• Yee, K. W. L., O'Brien, S. M. (2006). Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 81: 1105-1129 [Abstract] [Full Text]  
• O'Brien, S. N., Blijlevens, N. M.A., Mahfouz, T. H., Anaissie, E. J. (2003). Infections in Patients with Hematological Cancer: Recent Developments. ASH Education Book 2003: 438-472 [Abstract] [Full Text]  
• Earle, C. C., Chapman, R. H., Baker, C. S., Bell, C. M., Stone, P. W., Sandberg, E. A., Neumann, P. J. (2000). Systematic Overview of Cost-Utility Assessments in Oncology. JCO 18: 3302-3317 [Abstract] [Full Text]  
• Eisen, A., Rebbeck, T. R., Wood, W. C., Weber, B. L. (2000). Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancer. JCO 18: 1980-1995 [Abstract] [Full Text]  
• Hillner, B. E., Weeks, J. C., Desch, C. E., Smith, T. J. (2000). Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis. JCO 18: 72-72 [Abstract] [Full Text]  
• Kalil, N., Cheson, B. D. (1999). Chronic Lymphocytic Leukemia. The Oncologist 4: 352-369 [Abstract] [Full Text]  
• Retchin, S. M., Hillner, B. E. (1994). The Costs and Benefits of a Screening Program to Detect Dementia in Older Drivers. Med Decis Making 14: 315-324 [Abstract]  
• Mehrez, A., Gafni, A. (1993). Healthy-years Equivalents versus Quality-adjusted Life Years: In Pursuit of Progress. Med Decis Making 13: 287-292 [Abstract]  
• Pizzo, P. A. (1993). Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. NEJM 328: 1323-1332 [Full Text]  
• (1991). IMMUNE GLOBULIN FOR CLL: IS IT COST-EFFECTIVE. JWatch General 1991: 6-6 [Full Text]